A Study of Haploidentical Bone Marrow Transplant for Patients With Hematologic Malignancies

Stopped early · Phase 2

Conditions studied: Hematologic Malignancies

In brief

The primary objective is to determine overall survival 180 days after transplantation involving HLA-haploidentical stem cell/bone marrow graft, and post-transplant Cy.

Key facts

Study ID

NCT02623439

Run by

University of California, San Diego

People needed

10

Starts

2012-09-21

Expected to finish

2023-01-01

Last updated by the study team

2025-11-10

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age: Subjects 18-70 years old.
• Donor must be 18 years of age.
• HLA typing will be performed at high resolution. A minimum match of 5 out of 10 is required.
• Patients must have received multi-agent chemotherapy within 3 months of consent date (measured from the start date of chemotherapy).
• Acute Leukemias.
• Acute Lymphoblastic Leukemia in high risk 1st complete response (CR1)
• Acute Myelogenous Leukemia in high risk 1st complete response (CR1)
• Acute Leukemias in 2nd or subsequent Complete Response (CR)
• Biphenotypic/Undifferentiated Leukemias in 1st or subsequent Complete Response (CR).
• Burkitt's lymphoma: second or subsequent Complete Response (CR).
• Lymphoma
• Patients with adequate physical function
• Performance status: Karnofsky score 70-100%.

Where it is running

• UCSD Medical Center — La Jolla, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.